Head of Lilly’s oncology unit resigning
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
Health Care & Insurance
Articles
State lawmakers to take on unemployment insurance
Businesses with a history of laying off employees would pay more in unemployment insurance costs, and workers in industries where layoffs occur regularly would receive lower benefits under a bill Indiana lawmakers are preparing to take up.
Vanderbilt rejected by high court on Cialis patents
Supreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against Eli Lilly’s Icos subsidiary.
Zionsville retirement village plans $32 million expansion
Hoosier Village Retirement Center in Zionsville announced plans Monday morning for a $32 million project that will expand its campus and allow the center to add 50 full-time workers.
Lilly seeks to block imports of cancer drug copy
The local drugmaker told the International Trade Commission on Thursday that the generic version of Gemzar violates its patent on the process for making the active ingredient.
Lilly imaging drug fails to win FDA panel’s backing
Eli Lilly and Co.’s Amyvid isn’t ready to be approved to detect Alzheimer’s-related deposits in the brain, according to FDA advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results of brain scans are read consistently, they said.
FDA panel sees promise in Lilly imaging drug
A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical designed to help screen for Alzheimer's disease could be useful pending additional study and training for physicians.
California judge bars Conseco Life from boosting rates
A federal judge in Los Angeles ruled Wednesday that Carmel-based Conseco Life Insurance Co. may not follow through with a plan to raise policy rates for more than 50,000 mostly elderly policyholders.
Uptick in M&A activity suggests a turnaround
Fourth quarter helps to bolster 2010 deal-making.
Indiana companies prepping for burst of acquisitions
Conditions are ripe for a barrage of mergers and acquisitions to take place this year.
Daniels’ budget proposal wouldn’t cut hearing aids
State budget director Adam Horst said he misspoke when he told the State Budget Committee last week that Daniels&’ proposal would eliminate Medicaid coverage for hearing aids.
Carmel firm gets FDA approval for lice treatment
ParaPRO LLC’s treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
Health chief: Indiana needs more trauma center access
State Health Commissioner Greg Larkin says much of Indiana lacks the access to hospital trauma centers needed to treat victims of attacks like the one in Tucson that left U.S. Rep. Gabrielle Giffords of Arizona critically injured.
Evans dreams big as Clarian becomes IU Health
Clarian Health, which is set to change its name to Indiana University Health on Jan. 24, is relying on the academic expertise of its downtown Indianapolis hospitals to pull in patients from a wider swath of the state and the nation.
Down on luck, Lilly finds comfort in pets
Eli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
Lilly imaging drug isn’t ready for approval, FDA says
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer’s disease isn’t ready for approval, according to U.S. regulators.
Community Health plans $12M east-side medical complex
Construction is set to begin soon on Community Health Pavilion, a three-story, 55,000-square-foot medical building to be built on six acres at 7910 E. Washington St.
WellPoint headquarters snags $42M
Massachusetts-based Franklin Street Properties acquired the Monument Circle headquarters of insurance giant WellPoint Inc. late in 2010 for $42 million—a rich $196 per square foot—from an affiliate of locally based HDG Mansur.
Endocyte prices IPO stock
The West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch $80 million to $92 million.
Panel says Lilly’s Solpura isn’t ready for approval
Eli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that isn’t derived from pig parts.